abstract Given 
introduction
The challenges of allocating finite health care resources have spurred countries with public health systems to consolidate their health technology assessment (HTA) programs. Currently, countries such as Australia, Canada, and the United Kingdom (UK) are at the forefront when it comes to HTA processes 1 . The primary aim of HTA is to inform the decision-making process concerning the incorporation of new technologies in order to prevent the adoption of technologies that are of doubtful value for the health system 2 and ensure publicly accountable decision-making 3 . Law 12.401/2011 4 was a milestone in the context of the Unified Health System (SUS), Brazil's public health system, because it lays out the criteria and timeframes for the HTA process and established the National Commission for the Incorporation of Health Technology (CONITEC). The latter plays an advisory role to the Ministry of Health relative to decisions about the introduction, exclusion, or alteration of new pharmaceuticals, products, and procedures, as well as the elaboration or review of clinical protocols and treatment guidelines (CPTG).
The HTA process in Brazil has evolved considerably in recent years. However, it still requires improvements and has been identified as a research priority. This is due to rising healthcare costs, growth in life expectancy, an increase in knowledge of the health-disease process, and the continual acceleration of the rate of technological progress, creating pressure for the adoption of innovative technology, which needs to be assessed to ensure safety and clinical effectiveness.
HTA programs should be constantly analyzed and consolidated to ensure the development of effective, sustainable, and transparent processes in the SUS. With this in mind, this article outlines the history of HTA in Brazil and compares current processes in the country to those of countries at the forefront of this field.
Method
A descriptive study was conducted drawing on a literature review and document analysis of the HTA process in Brazil, Australia, Canada, and the UK.
The following documents were analyzed in relation to HTA processes in Brazil: (1) recent legislation concerning HTA in the SUS [4] [5] [6] ; (2) the electronic form used to submit an assessment request to CONITEC (FormSUS) 7 . In relation to the other countries, searches were conducted of the following databases: Medline/PubMed, Scopus, and Web of Science. The searches were conducted between March and May 2014 and updated in December 2016, using the following descriptors: Incorporation AND Technologies, health AND technology AND assessment, health AND technology AND assessment AND program, health AND technology AND evaluation, Canada AND Australia AND United AND Kingdom AND Brazil AND HTA. The literature review focused on documents concerning the countries selected for study. In addition to the aforementioned review, a document search was conducted of the following websites: www. health.gov.au/hta; www.cadth.ca; and www.nice. org.uk.
A comparative analysis was performed using a methodology proposed by the Center for Evidence-based Policy 8 , a collaboration of academic and governmental entities created in 2003 with the purpose of producing evidence to help address health policy challenges.
The comparative framework 8 , adopted to facilitate comparison with other studies, was designed to respond two questions about HTA: (1) what are the components of a public health resource allocation program, using HTA as a model; and (2) what are the objectives of each component of the program or process. Based on this framework and using the information obtained from the aforementioned review process, the components were organized into six broad domains, as shown in Chart 1.
Australia, Canada, and the UK were chosen because of the long history of HTA in these countries, the prominent role they have played in developing best practices in universal healthcare settings, and the availability of information on programs and processes in English. Programs with limited or no information on the evaluation of HTA processes and those where information was not available in English were excluded.
For the purposes of the study and to enable comparison with the literature, the concept of "technology" in the context of HTA was broadened to encompass procedures, medical services, and the organization and delivery of health, disease prevention, and health promotion services 8 . HTA in the countries selected for this study is conducted by the following government and arms-length bodies: Australia -the Medical Services Advisory Committee (MSAC); Canada -the The PLAC issues recommendations to the Minister of Health and Aging as to which prostheses should be included in the Prosthesis List and the respective minimum benefits to be paid. The PLAC is not required to assess the cost-effectiveness of prosthesis before making a recommendation of listing or as the basis for determining the benefit to be paid 10 . The PBAC is responsible for pharmaceuticals. Manufacturers are required to submit a detailed HTA report to the PBAC after receiving safety approval from the Therapeutic Goods Administration 9 . Specialist organizations issue a confidential expert opinion to the PBAC based on a critical analysis of the HTA reports. Since documentation is considered a trade secret, only an executive summary of the decision of the PBAC is published. In addition to manufacturers, assessment requests may be submitted by medical bodies, health professionals, and private individuals and their representatives 10 . The PBAC publishes guidelines inform stakeholders of what should be taken into consideration in deciding whether a pharmaceutical should be subsidized and provide guidance on the submission and decision process and the preparation of submissions 10 . To be included on the list of the Pharmaceutical Benefits Scheme, which provides funding for the majority of pharmaceuticals purchased in the 
canada
Canada has a publicly funded, decentralized national health-care system 13, 14 comprised of separate provincial and territorial health insurance plans 14 . Each plan determines how best to organize, manage, and deliver health care within their jurisdictions 14 , following the recommendations of the federal government 9 . The role of the federal government includes premarket approval of technology and price regulation, when applicable 14 . The first HTA program was introduced in Canada in 1988 and included actions at both national and local level 13, 14 . HTA was aimed at informing decisions on the adoption and withdrawal of health technologies, health insurance plan coverage, patient referral to other jurisdictions, and the development of specific programs 9, 13 . Although universities and other organizations have made a valuable contribution to HTA in Canada, this activity has been carried out in the main by government-funded programs with permanent assessment staff 13 . HTA in Canada focuses on clinical effectiveness and economic aspects, with few reports considering ethical and social issues 9, 13 . Owing to the decentralized nature of Canada's health system, HTA decisions are not implemented nationally 13 .
The Canadian Agency for Drugs and Technology in Health (CADTH) provides evidence-based information on the clinical and economic implications of pharmaceuticals and other health technologies (including devices, procedures, and systems) for the 13 provincial and territorial health insurance plans 14 . The CADTH is a nonprofit independent body that also assesses potential technology for future us 9 . In line with the increasing demand for assessment, there has been a growth in the number of local HTA initiatives in hospitals, local health authorities, and province across the country 14 . There is limited duplication of activities across HTA programs, which generally tailor analysis to the local context 9 . The stages of the CADTH process are briefly outlined in Health Technology Assessment and Optimal Use: Medical Devices; Diagnostic Tests; Medical, Surgical, and Dental Procedures. Version 1.0 (Canadian Agency for Drugs and Technologies in Health, 2015) 15 . The HTA process in Canada does not have clearly defined timeframes. Certain local initiatives suggest that it takes between two to three months from the submission of the assessment request to the issuing of the assessment report 14 . Information on the use of incremental cost-effectiveness ratio (RCEI) thresholds by decision-makers as a criteria representing acceptable cost-effectiveness was not identified 14 . 
United Kingdom
The UK's HTA Program dates back to the 1990s. Through widescale consultation, this independent government-funded research program, aims to identify the research priorities of the National Health System (NHS) and its patients 9 . NHS committees and civil society repre- sentatives classify demands in order of priority based on criteria such as disease burden, intervention effectiveness, cost-effectiveness, budgetary impact, and assessment timescale 9 . The profile of the program was raised with the establishment of the National Institute for Clinical Excellence in 1999, which was renamed the National Institute for Health and Clinical Excellence (NICE) in 2005. The difference between the two is that the latter not only conducts HTAs, but results are used in developing guidance for the NHS on the use of health technologies 16 . Such has been the impact of NICE that its activities have been confused with HTA 16 . NICE's role is not to determine whether a particular technology should be adopted in the NHS. Rather, the organization is charged with advising the bodies responsible for public policy formulation 9 . As well as a website, the Institute has its own journal (Health Technology Assessment) in which the majority of the results of HTAs are published. Research includes evidence synthesis, when there is wide body of evidence, and clinical studies to fill identified gaps 9 . NICE commissions an independent academic center or centers to prepare assessment reports for consideration by the technology appraisal committee, an independent entity made up of members from the NHS, patient organizations, academia, and industry 16 . NICE's HTA recommendations are reviewed every three years or when new data emerges and are adopted only in England and Wales 9 . Since the guidance issued by NICE to the NHS is intended to reflect the views of health professionals and patients, the pressure brought to bear by the pharmaceutical industry, patients' associations, political groups, and professional societies, among others, is minimized 9, 16 . New technology recommended for adoption by NICE should be made available by local health authorities within three months 9 . The success of HTA in the UK is attributed to the independence of the institutions involved, quality of the work, and involvement of patients and health professionals alike 9 . Weaknesses include difficulties in detecting failed technology, lack of information about allocation of resources for the adoption of new technology, and the length of time of the assessment process 9 . With respect to the latter, multiple technology appraisals take 54 weeks, while single technology appraisals require 39 weeks 16 . Though aware of the criticism surrounding the use of quality-adjusted life years as the measure of health gain, NICE uses this indicator to calculate the RCEI 16 . The upper and lower thresholds adopted by NICE are £20 000 and £30 000, respectively 16 . As from 2014, it was expected that the decision on whether to adopt new pharmaceuticals would be taken based on the value-based pricing 17 . This method incorporates other constructs into the QALY-based cost calculation, using a multi-criteria approach.
Brazil
The first formal event in Brazil dedicated to HTA took place in 1983 in the form of an international seminar promoted by the government and Pan American Health Organization 18 . On this occasion, discussions were centered around issues such as efficacy, cost-effectiveness, and technology transfer.
With Although Brazil has been taking part in international discussions surrounding HTA since the 1980s, it was only in 2006 that the country joined the International Network of Agencies for Health Technology Assessment (INAHTA), via the DECIT 18 . In 2006, the technology incorporation process had yet to be regulated. This situation changed with the establishment of the Commission for Technology Incorporation (CITEC) 19, 20 attached to the Ministry of Health, whose mission was to oversee the technology incorporation process 19 . Timeframes for the appraisal process, issuing of decisions and recommendations, and adoption of new technologies by the SUS were not defined and public consultation on appraisals and the participation of civil society representatives in the Commission were not mandatory , was guided by some important issues 23 : (i) the expansion of the health-industrial complex; (ii) the fact that the importation by developing countries of diagnostic and therapeutic methods designed in developed countries generally occurred without any assessment of expected effects and without considering the epidemiological characteristics and health infrastructure of the importing countries; (iii) the incipient nature of monitoring of the results and impacts of new technologies; (iv) the launch and diffusion of new technologies that have an impact on the health system and consequent pressure to adopt these technologies despite a lack of knowledge on their effectiveness and estimate of the financial resources necessary for their adoption. The general aim of the PNGTS is assure access to effective, safe technology thereby guaranteeing health gains, subject to available resources 23 .
The PNGTS 22 provides that the DECIT shall be responsible for the national coordination of HTA. Support to generate and synthesize scientific evidence relevant to HTA is provided by the Brazilian Health Technology Assessment Network (REBRATS). Established in 2011 by Ministerial Order 2.915 24 , REBRATS is "a network of collaborating centers and teaching and research institutions geared towards the generation and synthesis of scientific evidence in the field of health technology assessment (HTA) in Brazil and worldwide".
In 2011, Law 8.080 was altered by Law 12.401, which added a provision on therapeutic care and the incorporation of health technology in the SUS 4 . The main innovations introduced by this Law were: (i) the appraisal of applications based on evidence showing the effectiveness and safety of the technology and on system impact studies; (ii) the adoption of technology based on CPTG; (iii) the guarantee of public participation through representatives of the National Health Council (NHC); (iv) the establishment of timeframes for the assessment process, issuing guidance for the adoption, exclusion, or alteration of technology (180 days, extendable for another 90 days, starting from the date that receipt of submission is confirmed); (v) mandatory public consultation and public hearing for relevant cases before decision-making. However, Law 12.401 did not manage to put into practice the principle of comprehensiveness, one of the guiding principles of the SUS, given that "in the absence of coordinated actions, the incorporation of technology, per se, has little impact on the improvement of access" 24, 25 . Law 12.401 4 lays out criteria and timeframes for the incorporation of new health technology and created CONITEC. According to Decree 7.646 5 , the aim of CONITEC is to "advise the Ministry of Health on the incorporation, exclusion, or alteration of health technologies by the SUS, as well as on the constitution or alteration of clinical protocols and treatment guidelines". CO-NITEC brought major advances over the CITEC, which it replaced 26 . Thus, the processes previously overseen by the CITEC (incorporation, subsequent assessments, and abandonment) 1 are currently the responsibility of CONITEC.
HTA is conducted in the following stages: (1) initiation of an administrative process containing the health technology incorporation, exclusion, or alteration request; (2) documentation compliance check; (3) It is also important to highlight the role Brazil's health surveillance agency ANVISA plays in the technology life-cycle. Created at the end of the 1990s, it plays a role in both the health and economic spheres 1 . With respect to the former, it issues product licenses based on an appraisal of effectiveness, safety, and quality. With regard to the economic sphere, ANVISA is the Executive Secretary of the Drug Market Regulation Chamber (CMED), through which it undertakes economic appraisals to define the price of the pharmaceuticals that enter the domestic market. The price regulation follows a number of criteria, including 18 : the epidemiological characteristics of the disease, health and safety, budgetary impact, and the results of economic assessment. ANVISA used to be a member of the GT HTA 18 and is a member of the Plenary of CONITEC.
It is also worth mentioning the National List of Essential Medicines (RENAME), periodically updated since the 1990s, and the creation of the Multidisciplinary Technical Commission for Updating the National List of Essential Medicines (COMARE) in 2005. Updating the RENAME is currently one of the responsibilities of CO-NITEC's Technical Subcommittee for Updating Rename and the National Formulary 6 . In addition, CONITEC is an advisor on the Technical Subcommission for the Assessment of CPTG and Technical Subcommission for Updating the National List of Health Actions and Services (RE-NASES).
Under current legislation, the DECIT is charged with the national coordination and implementation of HTA, while REBRATS is responsible for generating and synthesizing scientific evidence. CONITEC, whose Executive Secretary (SE/CONITEC) is currently the DGITS, is currently responsible for technology incorporation, exclusion, and alteration activities. The roles and responsibilities of the DECIT and DGITS are laid out by Decree 8.065 27 .
It is important to note that, while in other countries HTA is conducted by government or arms-length agencies, in Brazil it is undertaken by a government commission whose executive secretary is a department of the SCTIE.
Discussion
The health technology incorporation process and HTA programs are not uniform across the countries. Differences occur in relation to decision-making authority, the scope of evidence reviews, length of time that programs have been in place/experience, and program components 8 . The findings show that the motivation behind the implementation of HTA programs is pretty much the same across countries. HTA programs across the world have arisen to contribute to resource allocation processes to assure the introduction of cost-effective technology to health systems. HTA programs date back around 35 years, with the majority being established in the last 20-25 years 28 . Brazil is one of the developing countries that have a well-established HTA program 29 . Australia, Canada, and the UK have internationally recognized HTA programs 1, 30 . Given that the health systems and economies of these countries differ significantly from those of Brazil, the components of their incorporation processes were not expected to be totally identical to those of Brazil's CONITEC processes. However, despite the fact that the regulatory framework for HTA in Brazil was established less than ten years ago (CITEC and subsequently CONITEC), there are more similarities than differences between these countries' processes and the CONITEC processes. This is illustrated by the fact that current legislation fits all the criteria/components 8 considered important for structuring a HTA program.
The main differences identified include the entitlement to appeal in certain cases (in Brazil and the UK 31 ), program assessment (absent in Brazil), topic selection (absent in Brazil), and timeframes for implementing guidance after its publication (in Brazil and the UK). In both Brazil and the UK, stakeholders are entitled to appeal against final decisions/recommendations. No information was identified on appeals processes in the other countries.
Unlike other countries, in the case of CO-NITEC, no explicit mention was found of program assessment to enhance HTA. In this respect, a sequential reading of the minutes of meetings of the Plenary of CONITEC between January 2012 and August 2014 show a constant concern with improving the work process 32 . For example, CONITEC introduced information technology tools to streamline the HTA process. With respect to communication, a report documenting the activities and output of the Plenary and hierarchically superior levels was produced. The Plenary also discussed matters relating to its area of responsibility with a view to promoting more interactive, enlightened, and robust technical discussions.
A search of CONITEC's website conducted on 30 September 2016 shows that the Commission promotes continuous improvement, including the following initiatives: (a) installation of a new computer system that permits the electronic management of HTA and technology incorporation processes in the SUS (e-GITS); (b) introduction of a form for bodies/institutions not attached to the SUS, individual, and other bodies/institutions with the SUS; (c) publication of the minutes of Plenary meetings and reports written in simple language, so that society can present considerations/comments regarding public hearings; (d) creation of a direct channel with the National Justice Council via email to respond questions raised by magistrates regarding the adoption of pharmaceuticals, products, or procedures by the SUS; (e) efforts to enhance communication between CONITEC and society aimed at promoting capacity building and public participation in HTA through the production of a monthly bulletin summarizing submissions and recommenda-tions and overview of activities and results for the period 2012 to 2014; (f) publication of the guide Entendendo a incorporação de tecnologias em saúde -como se envolver (Understanding health technology incorporation -how to get involved) in a special edition of the electronic magazine Revista Eletrônica Gestão e Saúde, produced by the University of Brasilia, dedicated to CONITEC; (g) creation of the program CONITEC in Evidence, with presentations on matters of interest via videoconference on a fortnightly basis.
Unlike the other countries, CONITEC does not use prioritization criteria to select topics for review. This important aspect of HTA programs helps ensure transparency. The main groups of criteria are 8 : technology alternatives; budgetary impact; clinical impact; controversial nature of proposed technology; disease burden; economic impact; ethical, legal, and psychosocial implications; availability and relevance of evidence; level of interest (from government, health professionals, and patients); timeliness of review; and variation in rate of use.
Timeframes for implementing guidance after its publication are defined in Brazil and the UK. These timeframes help ensure the effective monitoring of the implementation of HTA decisions/ recommendations.
Another difference is the composition of the committees. While the Plenary of CONITEC is made up of representatives of ministry of health secretariats, regulatory agencies, and other entities, in the other countries studied representation is prioritized considering the technical expertise necessary for conducting the HTA, regardless of institutional links. That is why the independence of the appraisals undertaken by CONITEC is questioned 30 , given that the majority of the members of the Plenary are subordinated to the Ministry of Health. Autonomy has been shown to be a desirable feature of HTA programs 28 , both in terms of budget and hierarchy.
It is important to note that differences concerning HTA and decision-making regarding the incorporation of technology influenced by the structure of the health system were not explored by this study. For example, although Brazil and Canada both have a federal system of government and publically funded health systems, in the former HTA assessment and decision-making is centralized, while in the latter assessment it is conducted by the federal government and decision-making is decentralized. A study undertaken with health professionals working in both the public and private sector 33 showed that the majority of individuals believed that the assessment process should be centralized but that the decision to incorporate healthcare technologies should be decentralized. The latter was justified by the country's regional differences in terms of population, needs, and priorities 33 . Finally, it is important to stress that the purpose of this review was to undertake a comparative analysis of the HTA models adopted by each country and therefore an assessment of how the processes work in practice is beyond the scope of this study.
The structure and functioning of CONITEC and the relevant bodies in the other countries is similar and it is clear that Brazil has made major strides in improving its fledgling HTA process. Further research on the HTA process in Brazil could provide important insights to inform measures to enhance access to quality healthcare and at the same time help address the challenge of soaring healthcare costs, upholding the principle of equity in the public health system and improving efficiency. collaborators SGG Lima: literature review; data collection, analysis, and interpretation; drafting of the content of the article; revision of the content of the article; approval of the final version to be submitted. C Brito and CJC Andrade: data analysis and interpretation; critical review of the content of the article; approval of the final version to be submitted.
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